新华财经北京2月27日电（记者沈寅飞）前程无忧发布的最新一期《人力资源白皮书》显示，高科技行 业在2025年以4.9%的调薪幅度高居各行业之首。尽管全球投融资环境有所波动，但在国家对人工智 能、半导体等关键领域的政策倾斜下，该行业对核心技术人才的竞争已进入"刚需"阶段。 在2025年全国重点城市月薪统计排名中，一线城市的薪资排名优势明显，其中上海（12742元／月）和 北京（12518元／月）表现最为突出，这反映出高新产业及高级人才密度对薪酬的强大支撑。而新一线 城市的薪资追赶速度正在加快，杭州（10165元／月）、南京（9624元／月）等薪酬水平接近广州（差 距<1000元），显示长三角经济圈的辐射效应。鉴于新一线城市生活成本相对较低，未来极有可能成 为"高性价比就业中心"。 制造业和汽车行业在2025年的调薪幅度分别为4.3%和4.1%。随着新能源汽车转型和智能制造的深入， 传统"蓝领"职位正在向"数字工匠"转型。随着汽车"数码产品"化的不断加速， 汽车算法工程师在一线城 市年薪可以达到384258元。 医药健康行业在2025年保持了4.4%的调薪幅度。在老龄化趋势和生物技术创新的双重驱动下，该行业 展现 ...

多年来，中国已成为全球生物技术供应链的关键后勤基地，如合成小分子化合物、开展临床前及临床研 究项目等。 于近日在旧金山举行的第44届摩根大通医疗健康年会上，笔者与多名企业创始人及投资者交流，他们共 同陈述了一个事实：中国已不再处于生物技术创新的边缘，而是结构性地嵌入其中。事实上，许多美国 公司，无论大小，越来越依赖中国、印度和新加坡等亚洲国家的供应链，以使极其昂贵且漫长的药物开 发过程变得更加高效。 除了分子合成领域，中国的临床研究生态系统也迅速成熟。2024年，中国开展的临床试验占全球总量的 近1/3。笔者与制药信息公司Panoptic Bio的联合创始人兼首席执行官塞巴斯蒂安·德·比尔斯进行了交流。 他曾在中国生活一年并研究生物技术生态系统，他说："我当时在中国顶尖大学清华大学交流学习，并 了解那里正在进行的研究。与许多生物技术公司、生物制药公司和投资者交流后，我看到了中国日益成 熟的生物技术生态系统。"他还提到了中国在科研领域具有多重优势，比如运营成本更低、可招募患者 数量庞大、数据基础设施完善。 若有人质疑中国是否已成为行业的首要关注对象，风险投资公司Flagship Pioneering首席执行官努 ...

Group 1 - The board of directors of Yuanda Holdings approved the establishment of a traditional Chinese medicine (TCM) seed industry company, with a unanimous vote of 14 in favor [1] - The company will invest 81.25 million yuan through its wholly-owned subsidiary, Yuanda Biological Agriculture Co., Ltd., in collaboration with Gansu Hebo Long Medicine Technology Co., Ltd. and Professor Shao Baoping's team [1] - The new company will focus on three core areas: the creation of quality resources and biobreeding technology for TCM materials like Codonopsis pilosula and Astragalus membranaceus, the development of soilless seedling breeding technology, and the deep development and commercialization of TCM health products [1] Group 2 - Codonopsis pilosula is a key TCM material known for its ability to enhance energy and nourish the lungs, with a market sales forecast of approximately 8.5 billion yuan in 2024, and a total market size of 14.86 billion yuan when including the entire industry chain [2] - The market for Codonopsis pilosula is expected to grow at an annual rate of 9% to 12%, potentially exceeding 13.5 billion to 28 billion yuan by 2030 [2] - Astragalus membranaceus is recognized for its multiple health benefits, with a projected market sales of around 18.5 billion yuan in 2024, and a total market size of 30 billion yuan by 2030, growing at an annual rate of 8% to 10% [3] Group 3 - Yuanda Biological Agriculture Co., Ltd. has established a comprehensive strategic development plan since 2021, focusing on core agricultural inputs such as biopesticides and biofertilizers [3] - The company aims to provide integrated support for the production of high-end functional health foods, covering the entire process from quality resource creation to standard control in processing [3] - The collaboration represents the first industrial chain layout in the TCM field for Yuanda Holdings, leveraging biotechnological innovation to upgrade the traditional TCM industry [4]

Group 1 - The China Securities Regulatory Commission (CSRC) issued supplementary material requirements for 10 companies, including Mingyu Pharmaceutical, which is required to clarify the compliance of its equity structure and reverse mergers [1] - Mingyu Pharmaceutical has submitted its application to the Hong Kong Stock Exchange, with Morgan Stanley, BofA Securities, and CITIC Securities as joint sponsors [1] - The CSRC requests legal opinions on various compliance issues related to equity structure, foreign exchange management, and investment regulations [1][2] Group 2 - Mingyu Pharmaceutical was established in 2018 and is a biotechnology innovation company with a dual growth engine: a robust clinical-stage oncology product portfolio based on proprietary antibody-drug conjugate (ADC) platforms and a novel PD-1/VEGF bispecific antibody (bsAb) [3] - The company is advancing its own immune assets that are in late clinical stages towards commercialization [3]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for 10 companies, including Mingyu Pharmaceutical, which is preparing for a listing on the Hong Kong Stock Exchange. The CSRC has requested clarifications on compliance regarding equity structure and reverse mergers [1][2]. Group 1: Regulatory Compliance - Mingyu Pharmaceutical is required to clarify the compliance of its equity structure and reverse mergers, including whether shareholders holding over 5% have fulfilled foreign exchange registration requirements and whether domestic entities have complied with outbound investment regulations [1][2]. - The CSRC has asked for legal opinions on whether the establishment of domestic operational entities, Minghui Hangzhou and Minghui Shanghai, has met foreign investment reporting obligations and foreign exchange registration [1][2]. Group 2: Share Capital and Shareholder Information - The company must provide details on whether any upper-tier investors in QimingVIll and QimingVILL-HC are prohibited from holding shares under legal regulations, and the specific arrangements of special shareholder rights and their impact on control [2]. - Recent shareholders, including Radiance, PK, and Chin, must be explained regarding their background, the reasons for shareholding arrangements, and the fairness of the share prices during the recent capital increases [2]. Group 3: Company Overview - Mingyu Pharmaceutical, established in 2018, is a biotechnology innovation company with a dual growth engine based on proprietary antibody-drug conjugate (ADC) platforms and a novel PD-1/VEGF bispecific antibody (bsAb) [3].

Core Viewpoint - Mingyu Pharmaceutical, founded by former Heng Rui executive Cao Guoqing, has officially submitted its IPO application to the Hong Kong Stock Exchange, focusing on oncology and autoimmune diseases, but has yet to achieve commercialization [1][3]. Financial Performance - The company reported no revenue for 2023 and 2024, with a revenue of 264.15 million RMB in the first half of 2025, primarily from a strategic partnership with Qilu Pharmaceutical [1][3]. - Cumulative losses reached 1.239 billion RMB by mid-2025, with net losses of 137.275 million RMB in 2023, 282.631 million RMB in 2024, and 167 million RMB in the first half of 2025 [2][3][4]. - Operating cash flow was negative for 2023 and 2024, at -143 million RMB and -146 million RMB respectively, turning positive to 102 million RMB in the first half of 2025 due to licensing fees from Qilu [4]. Research and Development - Mingyu Pharmaceutical has 13 candidate products in its pipeline, with 10 in clinical stages, but has not yet commercialized any products [3][5]. - The company plans to allocate 51% of its fundraising net proceeds to the development of two core products, MHB036C and MHB018A, with 26% for MHB036C and 25% for MHB018A [6]. Market Competition - The most advanced product, MH004, targets atopic dermatitis and has submitted a new drug application in China, facing competition from Heng Rui's products in a market projected to reach 14.9 billion USD in 2024 [5][6]. - The global market for atopic dermatitis drugs is expected to grow to 29.5 billion USD by 2035, indicating significant commercial potential [5]. Strategic Partnerships - The partnership with Qilu Pharmaceutical has been crucial for generating revenue, with a total transaction value of 1.345 billion RMB for rights in the Greater China region [3][4].

Core Insights - Mingyu Pharmaceutical Co., Ltd. has submitted an application to list on the Hong Kong Stock Exchange, with Morgan Stanley, BofA Securities, and CITIC Securities as joint sponsors [1] - The company, established in 2018, is a biotechnology innovator with a dual growth engine: a robust clinical-stage oncology product portfolio based on proprietary antibody-drug conjugate (ADC) platforms and a novel PD-1/VEGF bispecific antibody (bsAb) [1] - As of November 16, 2025, the company has 13 candidate products in its pipeline, with 10 in clinical stages, and expects to generate revenue from its autoimmune projects soon [1] - The oncology projects focus on advancing ADC monotherapy for later-line treatment and exploring combination therapies with PD-1/VEGF bispecific antibodies to innovate first-line cancer treatment [1]

Core Insights - Mingyu Pharmaceutical Co., Ltd. has submitted an application to list on the Hong Kong Stock Exchange, with Morgan Stanley, BofA Securities, and CITIC Securities acting as joint sponsors [1] - The company, established in 2018, is a biotechnology innovation enterprise with a dual growth engine: a robust clinical-stage oncology product portfolio based on proprietary antibody-drug conjugate (ADC) platform and a novel PD-1/VEGF bispecific antibody (bsAb) [1] - As of November 16, 2025, the company has 13 candidate products in its pipeline, with 10 in clinical stages, and expects to generate revenue from its autoimmune projects soon [1] - The oncology projects focus on advancing ADC monotherapy for later-line treatment and exploring combination therapies with PD-1/VEGF bispecific antibodies to innovate first-line cancer treatment [1]

Core Viewpoint - The company is changing its stock abbreviation from "Lude Environment" to "Lude Technology" to better align with its core product positioning in bio-fermentation feed and highlight the importance of biotechnology in its main business [1] Group 1: Company Name Change - The abbreviation change to "Lude Technology" reflects the company's focus on biotechnology and aims to enhance market recognition of its "biotechnology" attributes [1] - The new abbreviation encompasses the company's existing main business and product system, which is expected to improve brand recognition and professional image [1] Group 2: Brand and Market Positioning - The name "Lude Technology" is consistent with the full company name "Lude Biological Environmental Technology Co., Ltd." and better represents the company's identity as a modern biotechnology enterprise integrating innovation and ecological environmental protection [1] - This change is anticipated to strengthen brand consistency and support the company's long-term development strategy in the capital market [1]

Core Viewpoint - The company is changing its stock abbreviation from "Lude Environment" to "Lude Technology" to better align with its core product positioning in bio-fermentation feed and highlight the importance of biotechnology in its main business [1] Group 1 - The new abbreviation "Lude Technology" reflects the company's focus on biotechnology and its existing product system [1] - The change aims to enhance market recognition of the company's "biotechnology" attributes, improving brand visibility and professional image [1] - The new name is consistent with the company's full name, "Lude Biological Environmental Technology Co., Ltd," reinforcing its identity as a modern biotechnology enterprise that integrates innovation and ecological protection [1]